Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.

Na Zhang, Xing Gao, Yingchao Zhao, Meenal Datta, Pinan Liu, Lei Xu
{"title":"Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.","authors":"Na Zhang, Xing Gao, Yingchao Zhao, Meenal Datta, Pinan Liu, Lei Xu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas, which are benign tumors that originate from the nerve sheath and damage the nerve as they grow, causing neurological dysfunction such as hearing loss. Current standard radiation therapy can further augment hearing loss by inducing local damage to mature nerve tissue. Treatment with bevacizumab, a Vascular Endothelial Growth Factor (VEGF)-specific antibody, is associated with tumor control and hearing improvement in NF2 patients; however, its effect is not durable and its mechanism of action on improving nerve function is unknown. Anti-VEGF treatment can normalize the tumor vasculature, improving vessel perfusion and delivery of oxygen. It is known that oxygen is a potent radiosensitizer; therefore, combining anti-VEGF treatment with radiation therapy can achieve better tumor control and allow for the use of lower radiation doses, thus minimizing treatment-related neurological toxicity.</p>","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"1 2","pages":"51-55"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300073/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of rare diseases research & treatment","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas, which are benign tumors that originate from the nerve sheath and damage the nerve as they grow, causing neurological dysfunction such as hearing loss. Current standard radiation therapy can further augment hearing loss by inducing local damage to mature nerve tissue. Treatment with bevacizumab, a Vascular Endothelial Growth Factor (VEGF)-specific antibody, is associated with tumor control and hearing improvement in NF2 patients; however, its effect is not durable and its mechanism of action on improving nerve function is unknown. Anti-VEGF treatment can normalize the tumor vasculature, improving vessel perfusion and delivery of oxygen. It is known that oxygen is a potent radiosensitizer; therefore, combining anti-VEGF treatment with radiation therapy can achieve better tumor control and allow for the use of lower radiation doses, thus minimizing treatment-related neurological toxicity.

将抗血管内皮生长因子疗法与放射治疗合理地结合用于 NF2 裂血管瘤。
神经纤维瘤病 2 型的特征是双侧前庭分裂瘤,这是一种良性肿瘤,起源于神经鞘,在生长过程中会损伤神经,造成听力损失等神经功能障碍。目前的标准放射治疗会对成熟的神经组织造成局部损伤,从而进一步加重听力损失。贝伐单抗是一种血管内皮生长因子(VEGF)特异性抗体,对NF2患者的治疗与肿瘤控制和听力改善有关;但其疗效并不持久,而且其改善神经功能的作用机制尚不清楚。抗血管内皮生长因子治疗可使肿瘤血管正常化,改善血管灌注和氧气输送。众所周知,氧气是一种有效的放射增敏剂;因此,将抗血管内皮生长因子治疗与放射治疗相结合,可以更好地控制肿瘤,并允许使用较低的放射剂量,从而最大限度地减少与治疗相关的神经毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信